Atossa Therapeutics, Inc. (ATOS) Stock Price & Analysis
Atossa Therapeutics, Inc. (ATOS) fell 3.08% to USD 4.41 as of June 10, 2026 at 07:53 UTC, according to Nexqual real-time market data.
ATOS last closed at USD 4.55; the session ranged USD 4.36–4.58 on volume of 53,794 shares. Market capitalization is $37.98M, with a 52-week range of USD 3.76–19.35 (NCM). Source: Nexqual, June 10, 2026 at 07:53 UTC.
Key Statistics (as of June 10, 2026 at 07:53 UTC)
| Price | USD 4.41 |
|---|---|
| Change | ▼ 3.08% (down) |
| Previous Close | USD 4.55 |
| Open | USD 4.55 |
| Day Range | USD 4.36 – 4.58 |
| 52-Week Range | USD 3.76 – 19.35 |
| Volume | 53,794 shares |
| Market Cap | $37.98M |
| Exchange | NCM |
Technical Analysis (ATOS)
Nexqual's technical model rates ATOS "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.57 (neutral) |
| vs SMA50 | Below (USD 5.24) |
| MACD | -0.18 (negative) |
Analyst Ratings (ATOS)
Wall Street analysts rate ATOS "Strong Buy" based on 4 analysts, with a mean price target of USD 22.75 (range USD 20–25), per Nexqual as of June 10, 2026 at 07:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 22.75 |
| High Target | USD 25 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (ATOS)
| EPS Estimate | USD -1.16 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.11 vs est -1.22 ▲ beat |
| 2025-12-31 | USD -1.34 vs est -1.14 ▼ miss |
| 2025-09-30 | USD -1.05 vs est -1 ▼ miss |
| 2025-06-30 | USD -1.05 vs est -0.85 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:53 UTC.
Financials & Fundamentals (ATOS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -78.58% |
| Current Ratio | 4.92 |
| Total Cash | $31.72M |
| Total Debt | $0 |
| Free Cash Flow | $-21.23M |
Source: Nexqual, June 10, 2026 at 07:53 UTC.
Financial Health Score (ATOS)
Nexqual rates Atossa Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $32M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$33M |
| Efficiency | Critical — ROE -79%, ROA -45.5% |
Ownership (ATOS)
| Insider Ownership | +2.14% |
|---|---|
| Institutional Ownership | +18.88% |
| Shares Outstanding | 8.61M |
| Float | 8.58M |
| Short % of Float | +4.66% |
Source: Nexqual, June 10, 2026 at 07:53 UTC.
Leadership (ATOS)
Atossa Therapeutics, Inc. is led by Steven C. Quay FCAP (age 74), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 07:53 UTC.
| Chairman, CEO & President | Steven C. Quay FCAP (age 74) |
|---|---|
| Chief Financial Officer | Mark J. Daniel (age 48) |
| Senior Vice President of Research & Development | Janet Rose Rea MSPH, RAC |
| Senior Vice President of Business Operations | Delly Behen P.H.R. |
Major Backers & Investors (ATOS)
Notable institutional backers of Atossa Therapeutics, Inc. include Ameriprise Financial, Inc., Renaissance Technologies, UBS Group AG, according to Nexqual as of June 10, 2026 at 07:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ameriprise Financial, Inc. | 2.96% |
| Renaissance Technologies | 1.27% |
| UBS Group AG | 1.07% |
| Fidelity | 0.91% |
| Millennium Management | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.71% |
| Columbia Threadneedle | 2.57% |
| BlackRock | 1.55% |
| Geode Capital | 1.13% |
| State Street | 0.46% |
Source: Nexqual, June 10, 2026 at 07:53 UTC.
From Atossa Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
- Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAGX | Jaguar Health, Inc. | USD 2.82 | ▲ 0.71% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 11.46 | ▲ 3.52% |
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| CTRM | Castor Maritime Inc. | USD 2.18 | ▲ 2.35% |
| SENS | Senseonics Holdings, Inc. | USD 7.43 | ▲ 11.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:53 UTC. This page is informational and not investment advice.